The newly published report titled “Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market– By Trends, Industry Competition Analysis, Covid-19 Analysis, Revenue (US$ Millions) and Forecast Till 2035.” features in-depth analysis and an extensive study on the LBP and Microbiome manufacturing industry, exploring its significant factors.
According to the latest market research report by InsightAce Analytic, the Global Live Biotherapeutic Products And Microbiome Contract Manufacturing Market Size is valued at 230.8 Million in 2024 and is predicted to reach 1,456.9 Million by the year 2034 at a 18.1% CAGR during the forecast period for 2025-2034
Request For Free Sample Pages :
https://www.insightaceanalytic.com/request-sample/1152
In recent years, the field of microbiome research has experienced remarkable growth, positioning itself as a pivotal area in the development of next-generation medical treatments. While the impact of the microbiome on human health is well-established, ongoing research has broadened its potential across a variety of therapeutic and clinical applications.
Comprising a vast and diverse array of microorganisms residing within the human body, the microbiome exerts a significant influence on numerous physiological processes. Emerging scientific data highlights the potential of engineered live biotherapeutics—genetically modified microorganisms—to precisely target disease mechanisms, further reinforcing the critical role of microbial interactions in the management and prevention of chronic and complex conditions.
Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1152
The prominent players in the Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing industry include:
Quay Pharmaceuticals, Cobra Biologics Limited, Cerbios-Pharma SA, List Biological Labs, Inc., Arranta Bio, BacThera, Luina Bio Pty Ltd, 4D pharma plc, Paras Biopharmaceuticals Finland Oy, Capsugel, Deerland Probiotics & Enzymes, Paragon Bioservices, UAS Labs, Biose, Cobra Biologics, Cerbios, Inpac Probiotics, BJP Laboratories, S-Biomedic, Meteoric Biopharmaceuticals, BiomX, Universal Stabilization Technologies, Assembly Biosciences, Wacker Biotech, Chung Mei Pharmaceutical and Other Prominent Players.
Key Industry Developments from Leading Players:
- In Nov 2021, Bacthera and Seres Therapeutics announced a collaboration to manufacture SER-109, Seres’ lead product candidate for recurrent Clostridioides difficile infection (CDI). Under the terms of the agreement, Bacteria is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of s located on Lonza’s Ibex campus in Visp, Switzerland. The agreement between Bacteria and Seres Therapeutics aims to expand upon Seres’ initial commercial manufacturing supply chain
- In May 2021, Bacthera’s drug product facility in Basel, Switzerland, and by the Danish Medicines Agency at Bacthera’s drug substance facility in Hørsholm, Denmark, both facilities had been granted manufacturing licenses by the respective national health authorities. The permit will allow the Company to fulfill the scope of bringing innovative Live Biotherapeutic Products (LBP) to patients with unmet medical needs
- In Nov 2019, Arranta Bio has received an US$82 million funding round and a strategic partnership with Thermo Fisher Scientific.Through this partnersship with Thermo Fisher, Arranta has access to the company’s a wide range of product portfolio and services and provided materials to Thermo Fisher for use in gene therapy production
- In Oct 2019, 4D pharma plc announced research collaboration and option to license agreement with MSD, the tradename of Merck & Co., Inc. to discover and develop Live Biotherapeutics (“s”) for vaccines. Through this agreement, 4D’s proprietary MicroRx platform will be paired with MSD’s expertise in developing and commercializing novel vaccines to discover and develop s as vaccines in up to three undisclosed indications
- In April 2019, Hansen Holding A/S and Lonza AG equally shared approximately €90m ($101.5m) to establish a CDMO (contract development and manufacturing organization) for biotherapeutic products. The investment was in two phases, bagan with an update to Lonza’s existing facilities in Hørsholm, Denmark, for cGMP production of drug substances (anaerobic bacteria). It also equiped new facilities in Basel, Switzerland, for drug product development and manufacturing.
Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Regional Analysis:
In 2021, North America held the largest share of the global market, driven by substantial research and development (R&D) investments and the rapid adoption of advanced technologies. The region is expected to maintain its leadership position throughout the forecast period, supported by a strong commercial presence in live biotherapeutics and microbiome-based products, as well as the availability of biopharmaceutical contract manufacturers.
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1152
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Segments
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2022 to 2030 based on Product Manufactured
- APIs
- FDFs
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2025 to 2034 based on Type of Formulation
- Solid Formulations
- Oral Liquids
- Injectables
- Others
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2025 to 2034 based on Scale of Operation
- Preclinical Scale Operations
- Clinical Scale Operations
- Commercial Scale Operations
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2025 to 2034 based on Company Size
- Small-sized Companies
- Mid-sized Companies
- Large Companies
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2025 to 2034 based on Region
- Europe
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
North America Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2025 to 2034
- U.S.
- Canada
Europe Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2025 to 2034
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2025 to 2034
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2022 to 2030
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2025 to 2034
- South Africa
- GCC Countries
- Rest of the Middle East & Africa
Get More Information ::
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
